CLINICAL_TRIALS
trial_result
· 2019-06-10
Clinical Trial Update: Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone [Phase 3]
Summary
Phase 3 trial evaluating lapatinib plus trastuzumab versus trastuzumab alone in cancer; terminated with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Phase 3 | Status: TERMINATED | Results posted: 2019-06-10